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ABSTRACT
Ankylosing Spondylitis (AS) is a common autoimmune arthritis which prevalence ranging from 0.1% up 
to 1.4% globally. Furthermore, in Asian population the prevalence of AS was increasing overtime. Up until 
now, there were several treatment options available in treating AS in Indonesia. However, there was still some 
limitations in complete remission achievement and some have limitation in potential adverse drug reaction. 
Eventually, these affect both patients’s daily activity and their quality of life.
There were studies demonstrated the association between intestinal dysbiosis and inflammatory rheumatic 
disorders. Previous studies also presented there was an altered composition of gut microbiota in AS patients. 
Probiotic in the other hand, has been known previously for its efficacy in treating intestinal dysbiosis. Hence, 
this review aimed to identify potencies, efficacy and safety of probiotics as AS treatment options.
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ABSTRAK
Spondilitis ankilosa (SA) adalah penyakit artritis autoimun yang cukup banyak ditemukan, memiliki prevalensi 
beragam secara global (0,1%-1,4%). Pada populasi Asia, prevalensi SA terus mengalami peningkatan. Hingga 
saat ini, terdapat beberapa pilihan terapi yang tersedia di Indonesia. Namun, masih terdapat beberapa 
keterbatasan pada pasien untuk mencapai remisi secara komplit dan keterbatasan pada potensi efek samping 
obat. Akhirnya, hal-hal ini yang mempengaruhi baik aktivitas sehari-hari maupun kualitas hidup pasien. 
Beberapa penelitian menunjukkan hubungan antara disbiosis usus dengan penyakit rematik inflamasi. 
Terdapat adanya perubahan pada komposisi mikrobiota usus pada pasien SA. Sedangkan, probiotik telah 
diketahui efektif mengatasi disbiosis usus. Maka, review ini betujuan untuk mengidentifikasi potensi, efektivitas 
dan keamanan probiotik sebagai salah satu pilihan terapi SA.
Kata kunci: spondylitis ankilosa, mikrobiota usus, disbiosis, spondiloartritis, probiotik
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INTRODUCTION
Ankylosing Spondylitis (AS) is a common 
autoimmune inflammatory arthritis, which affects both 
patient’s daily activity and quality of life. Ankylosing 
Spondylitis (AS) is the most prevalence subtype 
among Spondyloarthritis (SpA). Prevalence of AS 
was ranging from 0.1% up to 1.4% globally, the mean 
AS prevalence was 16.7 cases per 10,000 persons in 
Asian population.1 Similarly, another study in Asian 
population showed the prevalence of AS in 2015 was 
52.30 per 100,000 persons, which increased linearly 
from 2010 to 2015 at a rate of 7.7% per year.2 In 2017, 
data from Rheumatology Clinic, Dr. Hasan Sadikin 
General Hospital, Bandung presented 4% patients 
had spondiloarthrosis. Ankylosing spondylitis was 
dominating among the spondiloarthrosis group (45%).3 
Up until now, there were several treatment options 
available. However, some have limitation in complete 
remission achievement and some have limitation in 
potential adverse drug reaction. Hence, additional 
supplementary treatment modality is still needed.4
 Intestinal dysbiosis was found to be associated 
with several autoimmune disease, including 
inflammatory rheumatic disorders. There were several 
mechanisms proposed in the etiology of AS, such 
as alterations of intestinal permeability, stimulation 
of immune responses, molecular mimicry, and so 
on. 5 While previous study presented that probiotics 
affected including the mesenteric lymph nodes that 
communicate with the systemic immune system. 
Probiotics produced critical metabolites (short-chain 
fatty acids, dietary tryptophan and probiotic-produced 
indoled derivatives) which have anti-inflammatory 
effects. 6 
Previous studies also showed different microbial 
composition was found in patients with AS. “Healthy” 
microbiota was considered as an interesting therapeutic 
strategy in order to restore intestinal homeostasis and 
manage autoimmune disease eventually.7, 8 Probiotic 
has been known previously for its clinical potential in 
treating diseases related with intestinal dysbiosis. The 
purpose of the review is to identify potencies, efficacy 
and safety of probiotics as AS treatment options. 
Human Microbiota and Autoimmune Diseases
Normal flora or microbiota colonizes human body 
as defense mechanism from many diseases. They 
can be found on skin, oral cavity, nasal mucosa, gut, 
genital and urinary tracts. Aging, geography and 
many external factors (diet, infection, medication) 
change the intestinal epithelial cells and microbiota 
composition.9-12 Human intestinal tract has up to 
1014 microorganisms, with more than 1 kg biomass. 
Microbiota composition varies at different anatomic 
locations along the gut, ranging from 1011 cells/g 
content in the ascending colon to 107–8 in the distal 
ileum and 102–3 in the proximal ileum and jejunum. 
Both anaerobes and aerobes were found in the bacterial 
community; majority of the population (60–90%) 
are Bacteroidetes and Firmicutes. Moreover, there 
were some fungal species in the components of 
microbiota,.13-16
Intestinal microbiota affects both innate and 
adaptive immunity, locally as well as systemically.7, 
10,16 Dysbiosis or alteration of its function and 
composition, are associated with autoimmune disease. 
The mechanism is by promoting T cells regulatory 
by cross reactivity between its metabolites and host 
immune system.17, 18 Dysbiosis affects proinflammatory 
and anti-inflammatory processes at the epithelial level, 
including at remote sites such as the joints.7, 8
ANKYLOSING SPONDYLITIS (AS)
Ankylosing Spondylitis (AS) is an autoimmune 
disease that often diagnosed in early adulthood and 
associated with significant disability and eventually 
reduces patient’s quality of life.19 Several therapeutic 
options are limited to nonsteroidal anti-inflammatory 
drugs (NSAIDs), DMARDs, tumor necrosis factor 
inhibitor (TNFi), physical therapy, or combinations 
of them. No data comparison of direct treatment 
responses to non-TNFi biologic agents or slow-acting 
anti rheumatic drugs (SAARDs) in patients with active 
AS who have contraindications to TNFi. Rituximab 
showed little benefit in patients who had not responded 
to prior treatment with TNFi. Furthermore, overall level 
of evidence supporting the use of non-TNFi biologic 
agents was very low. 20 Despite the development of 
biologic agent therapy in AS, there are drawbacks in 
the high cost of biologic therapy and associated risk 
of serious infection such as tuberculosis. Therefore, 
investigation of additional cheaper and safer therapies 
is still worth to be performed.21, 22
Probiotics for Ankylosing Spondylitis
Spondyloarthritis (SpAs) is a condition associated 
with MHC class 1 gene HLA-B27. AS is one the 
SpAs and associated with inflammatory bowel disease 
(IBD). AS and IBD are also considered as inter-related 
diseases which include arthritis and ileocolonic disease. 
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Early life exposure to pathogen was thought to reduce 
the risk of IBD.23 Stebbings et al presented that fecal 
samples from AS patients had higher sulphate-reducing 
bacteria (p = 0.0004), which was also had a role in the 
pathogenesis of inflammatory bowel disease.24 Altered 
intestinal microbiota has been proposed to have a 
role in AS pathogenesis. Study from Costello et al 
utilized 16S rRNA sequencing to determine that the 
microbial profile from terminal ileal biopsies differed 
significantly between patients with AS and healthy 
controls (p < 0.001), predominantly consisted of five 
families of bacteria Lachnospiraceae (p = 0.001), 
Veillonellaceae (p = 0.01), Prevotellaceae (p = 0.004), 
Porphyromonadaceae (p = 0.001), and Bacteroidaceae 
(p = 0.001).25 Yeoh et al also presented that increase 
Klebsiella species in AS patients intestinal has been 
proposed to be involved in pathogenesis of AS and 
IBD, however a proposed mechanism of molecular 
mimicry between Klebsiella and HLA B-27 was not 
strong enough to prove their pathogenic role in AS.23 
Interestingly, Tito et al demonstrated intestinal biopsy 
result from SpA patients showed strong association 
between intestinal inflammation and profile of mucosal 
microbiota. Furthermore, the microbiota genus 
Dialister was positively correlated with the Ankylosing 
Spondylitis Disease Activity Score (Spearman's 
rho = 0.62, false discovery rate-corrected q < 0.01).26
Many considerations of which mechanisms were 
involved in the pathogenesis autoimmune rheumatic 
diseases. Molecular mimicry was thought to be an 
initiating factor for autoimmunity. Previous studies 
proposed that the mechanisms between intestinal 
dysbiosis and rheumatic diseases (including AS) may 
be caused by altered intestinal permeability or loss of 
immune tolerance which leads to induce or activate 
Th17 T helper cells and Treg cells. Eventually this will 
increase the expression of regulatory cytokines, both 
T cells and antigenic material invasion to the joints. 
23,27 However, dysbiosis was considered to exacerbate 
immune disorder in genetic susceptible individual 
rather than accentuate an initial autoimmune disease 
attack.28
From Antibiotics to Probiotics
There were several studies targeting this intestinal 
dysbiosis in AS management. Antibiotic utilization 
such as moxifloxacin, was significant change in the 
mean of bath ankylosing spondylitis disease activity 
index (BASDAI) (p < 0.001), bath ankylosing 
spondylitis functional index (BASFI) (p < 0.001), 
physician’s global assessment of disease activity 
(p < 0.001), patient’s global assessment of disease 
activity (p < 0.001), and nocturnal spinal pain (p < 
0.001) after 12 weeks. There was significant change 
in the mean of ESR and CRP after 12 weeks (p < 
0.001). However, several adverse events were found 
such as nausea, headache and dizziness.29 Sulfasalazine 
altered bowel flora by decreasing the numbers of 
nonspring anaerobes and reduced enterobacteria 
antibody titrations during treatment for AS. Chen 
et al demonstrated a meta-analysis study regarding 
sulfasalazine, an antibiotic which was previously 
known as DMARDs in AS treatment. The study 
showed sulfasalazine significantly reduced spinal 
stiffness and ESR among the subjects (Chi-square = 
11.25, I2 = 64.4%, p = 0.02 and Chi-square = 22.11, 
I2 = 68.3%, p = 0.002, respectively). Among the 
studies, only one severe adverse event was reported, a 
generalized, erythematous, raised, pruritic eruption that 
was associated with nausea, anorexia, and insomnia. 
However, this study was limited to AS patients with 
early-stage disease, higher ESR (active disease), and 
peripheral arthritis.29,30 Minocycline, an antibiotic 
group was previously known as disease-modifying 
antirrheumatic drugs in rheumatoid arthritis treatment. 
Combination of immunomodulatory and anti-microbial 
properties of minocycline had been known for its 
efficacy in the treatment of multifactorial condition 
such as inflammatory bowel disease which has 
been linked with AS.31 Minocycline also altered gut 
microbiome by significantly decreased microbiome 
KEGG orthologous (KO) group proportion in fecal 
samples immediately after exposure to minocycline 
compared to placebo group (p < 0.05).32 However, no 
study presented minocycline effect on AS yet.
Restoring balance of intestinal microbiota should 
improve patient’s symptom, therefore instead of 
using antimicrobial therapy, probiotic were proposed 
to alter intestinal dysbiosis. Up to now, there 
were only three clinical trial published regarding 
probiotics in AS. A small uncontrolled intervention 
study showed supplementation of Lactobacillus 
acidophilus and Lactobacillus salivarius daily for 4 
weeks to 18 patients gave significant improvements 
in BASDAI (5.8 ± 1.5 vs 4 ± 1.8, p < 0.05) and 
pain symptom (VAS) (33.6 ± 10 vs 28.6 ± 6.3, 
p < 0.05).33 In contrary, another studies presented that 
probiotic had no significant improvement in BASDAI 
and BASFI. Randomized controlled trials (RCT) 
of probiotic treatment in AS were limited by short 
duration and showed inconsistent results. Consumption 
of probiotic containing Streptococcus salivarius, 
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Bifidobacterium lactis and Lactobacillus acidophilus 
for period of 12 weeks did not improve quality of 
life and disease activity in AS patients 34 Likewise, in 
another RCT by Brophy et al, of same duration, the 
use of probiotics containing lactobacillus salivarius, 
Lactobacillus paracasei, Bifidobacterium infantis 
and Bifidobacterium bifidum did not give significant 
clinical and statistical improvement of in AS over 
the placebo.35 There were no serious adverse events 
reported in these studies. The most common adverse 
events were change in bowel habit, nausea, flatus, and 
abdominal pain.33-35
CONCLUSION
Despite inconclusive results from the review, 
there were some evidences pointing to the benefit of 
using probiotic in AS patients. More research with 
larger number subjects, homogen and specific type of 
probiotic strain and dosage, specific duration of therapy 
are required to be conducted to verify the benefit of 
probiotics for AS.
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